Adoption of miniaturized bioreactors is a growing trend, replacing conventional bioreactor systems in the life sciences industry.
The introduction of miniaturized, disposable bioreactors, and micro platforms is boosting the adoption of such devices for the production and testing of new pharmaceutical products. High throughput miniaturized bioreactor systems decrease the time for cell culture process development, thereby accelerating biopharmaceutical development.
Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/31236
Key Takeaways of High Throughput Process Development Market Study
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/31236
For instance, Advanced Microscale Bioreactors is an automated microbioreactor system coupled with miniature single use bioreactors that delivers higher volume. With an established biopharmaceutical industry, North America leads the global high throughput process development market.
The global high throughput process development market is projected to exhibit a CAGR of 9% over the forecast period (2019 – 2029).
“Consistent efforts taken by market players to come up with advanced products such as single-use bioreactors, and their availability in emerging countries such as India, China, and Mexico, are creating a favorable atmosphere for the growth of the high throughput process development market”, says a PMR analyst.
Launch of Innovative Products – Key Strategy of Industry Giants
Key players such as GE Healthcare, Sartorius AG, Thermo Fischer, and Eppendorf are investing in the development of various innovative products in the high throughput process development market. Products such as GE Healthcare’s PreDictor plates for HTPD chromatography process, hardware & software solutions from Eppendorf AG such as New Brunswick BioCommand software, and New Brunswick’s BioFLo510 bioreactors are recently launched products by the leading companies. Software solutions launched lately by Tecan Group, such as the Fluent Gx Platform, and upcoming ground-breaking software platforms such as the MAPlinx OEM platform offer a wide range of applications in high throughput process development.
Moreover, the adoption of single-use bioreactors is likely to drive the growth of the high throughput process development market. Single-use bioreactors from GE Healthcare minimize cost and also provide time-efficient cleaning and other procedures. These bioreactors also increase annual production capacity of the product.
Access Full Report @ https://www.persistencemarketresearch.com/checkout/31236
More Valuable Insights on High Throughput Process Development Market
Persistence Market Research offers a unique perspective and actionable insights on high throughput process development market in its latest study, presenting historical demand assessment from 2014–2018 and projections for 2019–2029, on the basis of product type (tools & systems, consumables, software, and solutions & services), application (mammalian cell culture & microbial fermentation, process development & optimization, and others), process development (upstream process and downstream process) and end user (biopharmaceuticals, contract research & manufacturing organizations, academic & research institutes, and others), across seven major regions.
Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape
Next-Generation Sequencing Market –
Next Generation Sequencing Market Segmented by(By Application – Whole-genome Sequencing ,Exome Sequencing,Targeted Resequencing,De Novo Sequencing,RNA Sequencing,ChIP Sequencing,Methyl Sequencing,Others);By Technology- Targeted Sequencing & Resequencing,Whole Genome Sequencing,Whole Exome Sequencing.
Syndromes Progressive Ataxia Weakness Disorders Market –
Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Market Segmentation by Key Players- Abbott Laboratories, Acorda Therapeutics Inc., American Regent Inc., Baxter International Inc., Biogen Idec., Bristol-Myers Squibb, Cadila Healthcare Ltd., Eli Lilly and Company, Glaxosmilthkline Plc., Sanofi, Roche Holding Ltd., Pfizer Inc. and Novartis AG.
Persistence Market Research
305 Broadway,7th Floor
New York City, NY 10007
U.S. Phone - +1-646-568-7751
U.S.-Canada Toll-free : +1 800-961-0353
E-mail id - firstname.lastname@example.org
Website : www.persistencemarketresearch.com